Recent

% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • breezerwave breezerwave Sep 18, 2012 8:46 AM Flag

    What kind of news heading is this?

    It is called inaccurate news. Here is what Threshold reported:

    "09/17/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that data from a randomized open-label Phase 2b clinical trial of investigational hypoxia-targeted drug TH-302 in patients with advanced pancreatic cancer will be presented at the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria, taking place September 28 - October 2, 2012.

    The company announced in February 2012 that the study met its primary endpoint demonstrating a statistically significant 63% improvement (p=0.005) in progression free survival (PFS) for patients treated with TH-302 and gemcitabine versus gemcitabine alone. This represented a 2-month increase in PFS for patients treated with TH-302.

    New findings on overall survival, which was a secondary endpoint of the study, indicate that patients treated with gemcitabine alone had a median overall survival of 6.9 months compared with 9.2 months for patients treated with 340 mg/m2 TH-302 plus gemcitabine (HR: 0.955, 95% CI: 0.67-1.37, p=0.800) and 8.7 months for patients treated with 240 mg/m2 TH-302 plus gemcitabine (HR: 0.960, 95% CI: 0.67-1.38, p=0.827). While not statistically significant, the improvement in median overall survival is consistent with the improvement in median PFS reported previously. The trial was not designed to detect a statistically significant improvement in overall survival and included a cross-over component. Patients receiving gemcitabine alone who crossed over to receive gemcitabine plus TH-302 upon disease progression did contribute to an increase in survival of the control arm."

    Real simple as to drugs, first one has to learn out to learn to use a drug to treat a patient. Cure comes later. Treatment can be beneficial even if a person does not get cured. Some cancers are curable. Some not. There is no question TH-302 is a beneficial treatment.

    Sentiment: Strong Buy

 
THLD
0.38-0.03(-6.93%)Jun 24 4:00 PMEDT